Acrivon Therapeutics Common Stock Z Score

ACRV Stock   7.15  0.68  10.51%   
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Acrivon Therapeutics Piotroski F Score and Acrivon Therapeutics Valuation analysis.
  
At this time, Acrivon Therapeutics' Net Invested Capital is fairly stable compared to the past year. Capital Stock is likely to climb to about 26.6 K in 2024, whereas Net Working Capital is likely to drop slightly above 82.2 M in 2024. At this time, Acrivon Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Selling General Administrative is likely to climb to about 20.6 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 19.1 M in 2024.

Acrivon Z Score Analysis

Acrivon Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2021 2022 2023 2024 (projected)
Short and Long Term Debt Total5.6M5.0M5.7M3.9M
Total Assets106.6M181.2M208.4M106.3M

Z Score

 = 

Sum Of

5 Factors

More About Z Score | All Equity Analysis

Current Acrivon Therapeutics Z Score

    
  17.32  
Most of Acrivon Therapeutics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acrivon Therapeutics Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

First Factor

 = 

1.2 * (

Working Capital

/

Total Assets )

Second Factor

 = 

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

 = 

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

 = 

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

 = 

0.99 * (

Revenue

/

Total Assets )

Acrivon Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Acrivon Therapeutics is extremely important. It helps to project a fair market value of Acrivon Stock properly, considering its historical fundamentals such as Z Score. Since Acrivon Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acrivon Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acrivon Therapeutics' interrelated accounts and indicators.
0.90.850.85-0.57-0.960.96-0.720.90.870.260.85-0.520.990.880.990.980.880.730.8-0.52
0.90.990.99-0.33-0.970.84-0.91.01.0-0.020.99-0.790.881.00.880.861.00.570.89-0.79
0.850.991.0-0.19-0.950.76-0.870.991.0-0.171.0-0.790.821.00.820.791.00.440.89-0.79
0.850.991.0-0.19-0.950.76-0.870.991.0-0.171.0-0.790.821.00.820.791.00.440.89-0.79
-0.57-0.33-0.19-0.190.46-0.760.37-0.32-0.25-0.93-0.190.17-0.66-0.26-0.66-0.71-0.26-0.96-0.20.17
-0.96-0.97-0.95-0.950.46-0.910.81-0.97-0.96-0.12-0.950.66-0.95-0.96-0.95-0.93-0.96-0.66-0.810.66
0.960.840.760.76-0.76-0.91-0.730.830.790.490.76-0.520.990.80.991.00.80.880.72-0.52
-0.72-0.9-0.87-0.870.370.81-0.73-0.89-0.88-0.08-0.870.96-0.73-0.89-0.73-0.73-0.89-0.61-0.870.96
0.91.00.990.99-0.32-0.970.83-0.891.0-0.030.99-0.790.881.00.880.861.00.560.89-0.79
0.871.01.01.0-0.25-0.960.79-0.881.0-0.111.0-0.790.841.00.840.821.00.490.89-0.79
0.26-0.02-0.17-0.17-0.93-0.120.49-0.08-0.03-0.11-0.170.080.37-0.090.360.42-0.090.81-0.10.08
0.850.991.01.0-0.19-0.950.76-0.870.991.0-0.17-0.790.821.00.820.791.00.440.89-0.79
-0.52-0.79-0.79-0.790.170.66-0.520.96-0.79-0.790.08-0.79-0.52-0.79-0.52-0.53-0.79-0.41-0.811.0
0.990.880.820.82-0.66-0.950.99-0.730.880.840.370.82-0.520.851.01.00.850.80.77-0.52
0.881.01.01.0-0.26-0.960.8-0.891.01.0-0.091.0-0.790.850.850.831.00.510.89-0.79
0.990.880.820.82-0.66-0.950.99-0.730.880.840.360.82-0.521.00.851.00.850.80.77-0.52
0.980.860.790.79-0.71-0.931.0-0.730.860.820.420.79-0.531.00.831.00.830.840.75-0.53
0.881.01.01.0-0.26-0.960.8-0.891.01.0-0.091.0-0.790.851.00.850.830.510.89-0.79
0.730.570.440.44-0.96-0.660.88-0.610.560.490.810.44-0.410.80.510.80.840.510.43-0.41
0.80.890.890.89-0.2-0.810.72-0.870.890.89-0.10.89-0.810.770.890.770.750.890.43-0.81
-0.52-0.79-0.79-0.790.170.66-0.520.96-0.79-0.790.08-0.791.0-0.52-0.79-0.52-0.53-0.79-0.41-0.81
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition

In accordance with the company's disclosures, Acrivon Therapeutics Common has a Z Score of 17.32. This is 156.59% higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The z score for all United States stocks is 98.62% lower than that of the firm.

Acrivon Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acrivon Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acrivon Therapeutics could also be used in its relative valuation, which is a method of valuing Acrivon Therapeutics by comparing valuation metrics of similar companies.
Acrivon Therapeutics is currently under evaluation in z score category among related companies.

Acrivon Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Acrivon Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acrivon Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acrivon Therapeutics' value.
Shares
State Street Corporation2023-12-31
133.3 K
Dafna Capital Management Llc2023-12-31
131.4 K
Ubs O'connor Llc2023-12-31
93.4 K
Northern Trust Corp2023-12-31
80.1 K
Charles Schwab Investment Management Inc2023-12-31
68.5 K
D. E. Shaw & Co Lp2023-09-30
46.8 K
Jpmorgan Chase & Co2023-12-31
33.3 K
Bridgeway Capital Management, Llc2023-12-31
32 K
Morgan Stanley - Brokerage Accounts2023-12-31
25.6 K
Ra Capital Management, Llc2023-12-31
4.8 M
Perceptive Advisors Llc2023-12-31
M

Acrivon Fundamentals

About Acrivon Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Acrivon Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrivon Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrivon Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Acrivon Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Acrivon Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Acrivon Therapeutics' short interest history, or implied volatility extrapolated from Acrivon Therapeutics options trading.

Pair Trading with Acrivon Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acrivon Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Acrivon Stock

  0.72MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr

Moving against Acrivon Stock

  0.7MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.63KA Kineta Inc Financial Report 9th of May 2024 PairCorr
  0.52ME 23Andme HoldingPairCorr
  0.47MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to Acrivon Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acrivon Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acrivon Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acrivon Therapeutics Common to buy it.
The correlation of Acrivon Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acrivon Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acrivon Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acrivon Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Acrivon Therapeutics is a strong investment it is important to analyze Acrivon Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Acrivon Therapeutics' future performance. For an informed investment choice regarding Acrivon Stock, refer to the following important reports:
Check out Acrivon Therapeutics Piotroski F Score and Acrivon Therapeutics Valuation analysis.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Acrivon Stock analysis

When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Stocks Directory
Find actively traded stocks across global markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is Acrivon Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acrivon Therapeutics. If investors know Acrivon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acrivon Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.26)
Return On Assets
(0.29)
Return On Equity
(0.47)
The market value of Acrivon Therapeutics is measured differently than its book value, which is the value of Acrivon that is recorded on the company's balance sheet. Investors also form their own opinion of Acrivon Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acrivon Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acrivon Therapeutics' market value can be influenced by many factors that don't directly affect Acrivon Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acrivon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acrivon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acrivon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.